{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017765","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.399749+00:00","generated_at":"2026-06-21T19:46:02.110595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aytu BioPharma posts record Q1 revenue of $27.7M, first positive adjusted EBITDA of $1.4M","bullets":["Record quarterly net revenue of $27.7M, up 26% YoY; Rx segment revenue grew 34% to $18.7M.","Positive adjusted EBITDA of $1.4M vs. ($4.2M) loss a year ago; net loss narrowed to ($2.9M).","Indefinitely suspended clinical programs (AR101/enzastaurin), saving over $20M in future study costs.","Leadership changes: Jarrett Disbrow as Chief Business Officer, Topher Brooke as COO, Ryan Selhorn as EVP Finance.","Extended interest-only period on Avenue debt to Jan 2024, saving $3M in 2023 principal payments; warrant exercise price reset to $0.43."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017765","json":"https://secwatch.observer/filing/0001558370-22-017765.json","markdown":"https://secwatch.observer/filing/0001558370-22-017765.md","text":"https://secwatch.observer/filing/0001558370-22-017765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/0001558370-22-017765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/aytu-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:46:02.110595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4d8e73df8fbd298317668ae1a4a4b07a4f30c87","claim":"AYTU BIOPHARMA, INC reported the first quarter of fiscal year 2023 ended September 30, 2022 results: revenue $27.7 million.","evidence_excerpt":"Q1 2023 Commercial Highlights (3 months ending September 30, 2022) · Total net revenue was $27.7 million, a new quarterly record, and an increase of 26% over the $21.9 million in net revenue in the year ago quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022017765/0001558370-22-017765-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of fiscal year 2023 ended September 30, 2022"},{"label":"Revenue","value":"$27.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}